Previous 10 | Next 10 |
2024-02-22 20:49:13 ET More on etc. Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript Hooker Furnishings: Temporary Headwinds Haven't Created An Attractive Buying Level MP Materials Corp. (MP) Q4 2023 Earnings Call Transcript Crude oil edges high...
2024-02-22 20:48:06 ET Vir Biotechnology, Inc. (VIR) Q4 2023 Results Conference Call February 22, 2024 04:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Ph...
2024-02-22 16:27:48 ET More on Vir Biotechnology Sticking With Vir Biotechnology JP Morgan cuts Vir to neutral, cites hepatitis drug franchise concerns Vir Biotechnology to shed 12% of workforce as part of corporate restructuring Seeking Alpha’s Quant ...
– Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% (6/6) of participants had HDV RNA less than the lower limit of quantification – – Phase 2 SOLSTICE trial on track to...
2024-02-20 16:33:24 ET More on Vir Biotechnology Sticking With Vir Biotechnology JP Morgan cuts Vir to neutral, cites hepatitis drug franchise concerns Vir Biotechnology to shed 12% of workforce as part of corporate restructuring Read the full article on Se...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family. The Company has initiated a search for a successor. “Phi...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Februa...
2024-01-29 14:19:18 ET More on Vir Biotechnology Sticking With Vir Biotechnology Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript Vir Biotechnology to shed...
2024-01-17 15:20:13 ET Summary Today, we revisit Vir Biotechnology, Inc. for the first time in nearly a year. The stock took a tumble in July on the back of the trial setback, but the company has multiple shots on goal within its advancing pipeline. The company also has some $...
2024-01-12 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NYSE Market:
– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data readouts on track for the fourth quarter 2024 – – $1.51 b...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the ...
Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the ...